TetraLogic Pharmaceuticals is a clinical-stage biotechnology company dedicated to the development of novel immunotherapeutics for oncology and infectious diseases. The company’s proprietary platform harnesses self-replicating RNA virus-like particles to stimulate robust cellular and humoral immune responses. TetraLogic’s lead candidates are designed to target solid tumors and persistent viral infections by delivering antigen payloads that activate the body’s innate and adaptive immune systems.
The company’s pipeline includes multiple investigational products in preclinical and early-phase clinical studies. In oncology, TetraLogic is advancing candidates aimed at melanoma, colorectal cancer, and other tumor types characterized by poor prognosis under existing therapies. The approach combines targeted antigen expression with localized immune activation to overcome tumor-associated immune suppression. In parallel, TetraLogic is exploring broad-spectrum antiviral vaccines that leverage the same replicon technology, with programs focused on emerging zoonotic threats and chronic viral pathogens.
Founded in the early 2000s, TetraLogic has grown from a small research venture into a publicly traded enterprise on the OTC market under the symbol TLOG. Throughout its history, the company has established research collaborations with academic institutions and government agencies, securing grants and partnerships to accelerate the development of its pipeline. TetraLogic operates research laboratories in the United States and maintains strategic alliances in Europe to support manufacturing and clinical operations.
Leadership at TetraLogic comprises seasoned executives and scientists with deep expertise in virology, oncology, and drug development. The management team includes veterans who have held senior roles at leading pharmaceutical companies and major research universities. Under their guidance, TetraLogic continues to expand its platform capabilities, with the goal of delivering first-in-class therapies that address unmet medical needs across oncology and infectious disease markets.
AI Generated. May Contain Errors.
